The purpose of this study is to evaluate the safety of repeated TP10 dosing in pediatric and
adult patients with C3G and to evaluate the activity of TP10 in pediatric and adult patients
with C3G, as measured by the proportion of patients with normalization of serum C3, serum C3
breakdown products, or alternative pathway (AP) complement activity.